Minimhal® and CombiHaler®: their demonstrated effectiveness presented at the Respiratory Failure and Mechanical Ventilation Conference (RF&MV)

Respiratory Failure and Mechanical Ventilation Conference banner

The Respiratory Failure and Mechanical Ventilation Conference (RF&MV) took place in Berlin from 13 to 15 February. This conference allowed healthcare professionals to update their knowledge in the field of artificial ventilation. This technique is commonly used in intensive care units or at home for long-term treatment 1,2.

Performances noticed by the RF&MV scientific committee


For many years, OptimHal-ProtecSom laboratory has carried out research on drug delivery in the context of mechanical ventilation. This research made it possible to develop CombiHaler® and MinimHal® spacers.

A study comparing effectiveness of these spacers to standard equipment used in mechanical ventilation circuits caught the attention of the scientific committee of RF&MV. This study (carried out by Dr. Eckes) was selected to be presented as an e-poster short talk by Dr. Vanlaeys, R&D project manager at OptimHal-ProtecSom laboratory.  

Le Dr Alison Vanlaeys de Protecsom Optimhal à la Respiratory Failure and Mechanical Ventilation Conference RF&MV

Alison Vanlaeys de Protecsom Optimhal à la Respiratory Failure and Mechanical Ventilation Conference RF&MV

Drug delivery in mechanical ventilation via MinimHal® and CombiHaler®: a proven effectiveness


Artificial ventilation is driven by a ventilator connected to the patient by a circuit. This process allows to maintain the patient’s breathing in case of insufficient respiratory capacities. Drugs can be delivered to the patient by different kinds of devices disposed in ventilation circuit (typically a T-piece or a spacer) which allow to connect a pressurized metered dose inhaler or a nebulizer.

This study showed that using CombiHaler® or MinimHal® instead of a T-piece allows to double the salbutamol inhaled dose. These results were reproducible using adult and pediatric respiratory patterns.

CombiHaler® and MinimHal® also stand out for their versatility. These spacers can be used to deliver drugs thanks to a pressurized metered dose inhaler and / or a nebulizer.

Discover the study


  1. Slutsky AS. History of Mechanical Ventilation. From Vesalius to Ventilator-induced Lung Injury. Am J Respir Crit Care Med. 2015;191((10)):1106–15. 10.1164/rccm.201503-0421PP 
  2. Manthous, C., Tobin, MJ. A Primer on Critical Care for Patients and Their Families. 1st issued in 2001; 2017-2018 Update to be posted on

A study on improvement of life quality of patients using ProtecSom dust mite covers presented at the World Allergy Congress (WAC)

The World Allergy Congress (WAC), an international conference on allergology, took place in France (Lyon) on December 12th to 14th, 2019. This event allowed many actors in the fight against allergy to update their knowledge on this pathology affecting up to 40% of the worldwide population.1

With more than 15 years of experience in dust mite covers manufacturing, the OptimHal-ProtecSom lab presented a study in the form of poster communication selected by the WAC Scientific Committee. The aim of this retrospective study was to determine and quantify the benefit from the use of dust mite covers on the life quality of allergic patients.

A significant improvement in life quality for patients who use ProtecSom dust mite covers

ProtecSom anti-mite covers are certified medical devices which form a protective barrier preventing the passage of mites thanks to their unique patented weaving process. A declarative study demonstrated the benefit of dust mite covers on the perception of allergy-related symptoms.

This study revealed a significant increase in life quality following the use of the ProtecSom dust mite covers and implementation of complementary measures to control patient’s environment. An improvement in allergy-related symptoms (nasal discharge, cough, eye inflammation, itchy skin and breathing problems) was observed in all age groups asked. The overall symptom reduction was 62%.

Take a look to the study


  1. Pawankar R, Canonica GW, ST Holgate ST, Lockey RF, Blaiss M: The WAO White Book on Allergy (Update. 2013).

Presentation of an innovative valve holding chamber prototype aiming at cure newborns during the CPLF congress in Paris



The 24th French Language Pneumology Congress (CPLF) took place in Paris on January 24th. This annual conference allows to more than 5,000 healthcare professionals to discuss the discoveries and innovations in the treatment of allergy and asthma.



A medical device noticed by the scientific community

Only 30% of newborns are able to inspire enough to open the inspiratory valve of valve holding chambers.1 Moreover, most of valve holding chamber have a dead volume not allowing to children under 1 year of age to inhale efficiently their treatment.2 Facing these facts, the OptimHal-ProtecSom team has developed NeonatHal®, a valve holding chamber without inspiratory valve. This prototype was introduced by Thierry Porée, the Scientific Director of OptimHal-ProtecSom, to the scientific community during a communication selected on abstract by the CPLF Scientific Committee.



Already promising results

The results are very clear, NeonatHal® use allows to double the delivery of bronchodilators at their action site. These results pave the way toward new studies aiming at determining until what age NeonatHal® offers a clear clinical benefit for the treatment of asthma.


  1. Herbes, C. et al. Metered‐dose inhaler therapy with spacers: Are newborns capable of using this system correctly? Pediatr Pulmonol 54, 1417–1421 (2019).
  2. Amirav, I. & Newhouse, M. T. Review of optimal characteristics of face-masks for valved-holding chambers (VHCs). Pediatr. Pulmonol. 43, 268–274 (2008).

The OptimHal-ProtecSom Laboratory exposes its work during DDL 2019 (Drug Delivery To The Lungs)


The Aerosol Society organized its 30th DDL congress in Edinburgh from December 11 to 13.

It is a must-attend annual forum for scientists, academics, clinicians, regulatory and industry experts involved in the development of inhalation medication. On the program, five thematic sessions each with a combination of conferences by experts in the field of inhalation and by students working to advance respiratory science.


During this congress, Thierry Porée, scientific director of the OptimHal-ProtecSom Laboratory, presented at a conference our latest work on the inhalation chamber for CombiHaler® mechanical ventilation circuits. An innovation !



CombiHaler® is an inhalation chamber for mechanical ventilation. It enables the simultaneous administration of medication by a metered dose inhaler and a vibrating mesh nebulizer.

It is intended to be used in hospitals, intensive care, or home hospitalization.



Research and results of interest have been presented by the OptimHal-ProtecSom laboratory.

Heating and humidifying a mechanical ventilation circuit is needed to protect the lungs of patients under invasive respiratory assistance. However, heat and humidity reduce the dose of aerosols delivered to the patient. We assessed the impact of heat and humidity on in vitro drugs delivery using pressurized metered dose inhaler and vibrating mesh nebulizer with CombiHaler®

This work has demonstrated the advantage of using an inhalation chamber both with a vibrating mesh nebulizer and with a metered dose inhaler, in comparison with the usually used T-pieces.

It also demonstrated that switching off the heated humidifier located in a mechanical ventilation circuit during drug administration did not increase the delivered dose and that the position of the inhalation chamber in the heated and humidified mechanical ventilation circuit had an important influence on this delivered dose.



Découvrir l’étude

ERS: European Respiratory Medicine Event

The European Respiratory Society (ERS), organized its 29th congress from 28 September to 02 October 2019 in Madrid, Spain. Showcasing the excellence of respiratory medicine, it is an essential event for all pneumology professionals and the patient associations concerned. It brings together more than 15,000 doctors, scientists and other specialists in respiratory medicine (research laboratories, etc.).


This event promotes scientific research and provides access to educational resources on diseases such as asthma, the heart of the Optimhal-Protecsom laboratory.




Promising resultats presented by OptimHal-ProtecSom


The Optimhal-Protecsom laboratory actively participated in this knowledge sharing by presenting its latest research on several inhalation chambers for mechanical ventilation circuits, including Combihaler.


Combihaler® is an inhalation chamber for mechanical ventilation systems. It allows for the simultaneous administration of metered-dose drugs and a mesh nebulizer.

In this study, the in vitro performances of several spacers, including CombiHaler®, were evaluated for drug delivery with pressurized metered dose inhaler (pMDI) and vibrating mesh nebulizer, in comparison with T adapters usually used, in an adult mechanical ventilation model.


Results showed that in vitro drug delivery is higher when using a spacer instead of T pieces, with both a pMDI and a vibrating mesh nebulizer.


CombiHaler has similar or higher in vitro performances than other spacers and permits the use of both a pMDI and a vibrating mesh nebulizer without dismantling the breathing circuit : these are new successful results which strengthen our goals and our purpose of continuous improvement. 


Each year, the Optimhal-Protecsom laboratory invests more than 25% of its turnover in research. This is an essential point for designing tomorrow’s medical devices with a constant goal : to improve the quality of life of patients and facilitate the work of caregivers.


Discover the study


Coughing, runny nose, stinging, itching, it’s red… What if it was an allergy to mites? It’s the high season!

In autumn, all the conditions are met to promote the proliferation of dust mites: heated housing, less airy, closed windows and reduced light are all factors that contribute to the concentration of allergenic particles in your indoor environment.


More than 3 in 10 French people suffer from allergy to dust mites and many people ignore it or minimize its consequences.



So, are you one of those allergic people who ignore themselves ? 

Among the 35% of French people who say they are allergic, 1 in 2 people considers that it is not a “real” disease and is thus exposed to a sometimes very serious evolution of their allergic disease. Asthma has an allergic origin for 80% of children and 50% of adults.

Respiratory illness is not to be taken lightly!

The association Asthme & Allergies calls, through an information and awareness campaign, patients and parents of allergic children to mobilize to better and faster detect allergy to dust mites in order to avoid these evolutions to asthma or other severe pathologies.


The Protecsom Laboratory, a specialist in allergen protection and improvement of the quality of life of patients, actively participates in this new awareness campaign of the association Asthma & Allergies, with several other partners and actors in the fight against mite allergy.


Visit the website


A 100% digital campaign !


This awareness campaign is deployed in the media and on social networks.
Discover four videos that feature the different symptoms of mite allergy (Eternity, Difficult Awakening, Runny Nose, etc.) and a page to answer all questions related to mite allergy. (Symptoms, Solutions and Risks).
A game created by the association Asthma & Allergy may also allow you to gain your protection. Be vigilant !